|
Reference #:
2005-016
Inventors/Contributors
Michael L. Hutton, Ph.D., Jada M. Lewis, Ph.D.
Description
These transgenic mice have regulatable tau expression and profound neurofibrillary pathology, neurodegeneration and memory impairment. The key features are (1) Protein expressed is human tau P301L; (2) Expression of transgenic tau is restricted to the forebrain; (3) Mice develop memory impairment by 2.5 months; (4) Mice develop argyrophilic neurofibrillary tangles by 4 months; (5) Mice develop gross atrophy of the brain by 5.5 months; (6) Transgenic tau can be suppressed by administration of the tetracycline analog, doxycycline.
Patent Status
Pending |
|
Contact
Susan L. Stoddard, Ph.D., Licensing Manager
sstoddard@mayo.edu
|
|
Mayo Foundation for Medical Education and Research
Office of Technology Commercialization
Centerplace 4
200 First Street SW
Rochester, MN 55905
|
Phone: (507) 284-1222
Fax: (507) 284-5410
|
|
|
